bioStrategies’ study supports $249m sale of Merck’s Aggrastat® to Iroko
FOR IMMEDIATE RELEASE
Chicago, IL — January 31, 2008
bioStrategies' commercial due diligence helps support Irokos’s purchase of Aggrastat™ from Merck for $249m.
Iroko Pharmaceuticals, LLC acquired from Merck the ex-US rights to Aggrastat® (tirofiban hydrochloride), a GP IIb/IIIa product used to treat patients with acute coronary syndrome.
For more information about the study, please contact Mike Kaestle.